Liver Cirrhosis, Alcoholic Clinical Trial
— SMILEOfficial title:
A Randomized, Pragmatic, Outcome-assessor-blinded Study of an SMS-message-based Lifestyle Intervention in Patients With Decompensated Liver Cirrhosis
Verified date | November 2021 |
Source | Frederiksberg University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To investigate whether simple reminders about healthy lifestyle sent via mobile phone text messages can improve the liver cirrhosis severity and prognosis (as assessed by the MELD score supported by the Child-Pugh score) among patients with liver cirrhosis that have been through a 12-week supervised and facility-based physical exercise training program and in-patient rehabilitation.
Status | Terminated |
Enrollment | 9 |
Est. completion date | December 2019 |
Est. primary completion date | October 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult, i.e. age 18 years or above. 2. Is attending the liver cirrhosis rehabilitation clinic at Bispebjerg hospital; i.e., has alcohol-induced liver cirrhosis or hepatorenal syndrome and has at least once experienced severe decompensation in the form of hepatic encephalopathy or variceal haemorrhage. 3. Has attended at least 50% of the scheduled sessions in the 12 week run-in physical exercise program 4. Is the owner of a mobile phone capable of receiving SMS-messages 5. Has signed informed consent 6. Reads and speaks Danish Exclusion Criteria: 1. Any condition that in the opinion of the investigator puts an otherwise eligible participant at increased risk by participation or otherwise make the person unfit for participation |
Country | Name | City | State |
---|---|---|---|
Denmark | Bispebjerg Hospital, Department of Physical and Occupational Therapy | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Marius Henriksen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Continuous Reaction Time | Continuous Reaction Time (CRT) is a 10-minute computer-based test measuring the patient's reaction-time to a beep-sound and the patient's ability to concentrate. CRT-index below 1.9 is compatible with minimal hepatic encephalopathy . | week -12, 0, 12, 24 | |
Other | Portosystemic Encephalopathy test | The Portosystemic Encephalopathy test (PSE) measures complex cognitive functions such as attention, accuracy, working speed, and visual orientation. It is a paper-and-pencil test consisting of five subtests: Digit Symbol test, Number Connection Test A, Number Connection Test B, Serial Dotting Test, and Line Tracing Test. Calculating the test score from the seconds spent on each subtest takes 5 minutes. The summed test score, the portosystemic hepatic encephalopathy score (PHES), ranges from 218 to 6, and a result below 24 is abnormal. | week -12, 0, 12, 24 | |
Primary | Change in The Model for End-Stage Liver Disease (MELD) score | The MELD is a reliable measure of mortality risk in patients with end-stage liver disease. The MELD is based on a mathematical equation.
The MELD score is calculated using the following formula: MELD Score = 9.57 x ln (creatinine mg/dL) + 3.78 x ln(bilirubin mg/dL) + 11.2 x ln(INR)+ 6.43 |
week -12, 0, 12, 24 | |
Secondary | 10.2.1.1 Child-Pugh score | week -12, 0, 12, 24 | ||
Secondary | Quality of life, SF-36v1 | 10.2.2.1 Quality of life, SF-36v1 Short Form-36v1 is a standardised patient-reported instrument for use as a measure of health outcome and quality of life | week -12, 0, 12, 24 | |
Secondary | SOKRATES questionnaire | SOKRATES8a is a standardised patient-reported instrument for use as a measure of readiness for change in alcohol abusers | week -12, 0, 12, 24 | |
Secondary | Sickness Impact Profile (SIP) questionnaire | The Sickness Impact Profile (SIP) questionnaire is a 136 items generic health status measure | week -12, 0, 12, 24 | |
Secondary | Six-Minute Walk Test | The Six-Minute Walk-Test (6MWT) assesses general physical function. The test is performed in an undisturbed hospital corridor marked every 2 meters with coloured tape on the floor; starting and turning points marked by cones. Subjects are instructed to walk as fast as they can. They are allowed to stop or rest during the test if necessary and walking aids are allowed. The distance in meters covered during the 6 minutes is the outcome of the test. | week -12, 0, 12, 24 | |
Secondary | 30-seconds chair stand test | The 30-seconds chair stand test (30-s CST) is performed in an undisturbed room with hands crossed against the chest. It is one of the most important functional evaluation clinical tests because it measures lower body strength and relates it to the most demanding daily life activities. A 30-s CST consists of standing up and sitting down from a chair as many times as possible within 30 seconds. | week -12, 0, 12, 24 | |
Secondary | Muscle Power | The Leg Extensor Power Rig will be used to measure muscle power (force x velocity) in a non-invasive way. The participants will be in a seated position and a single explosive limb extension will accelerate a flywheel from rest. The participants will be instructed to kick the pedal as hard and fast as possible. Repeated kicks are performed, until a significant decline in power is observed. The kick with maximal power is the result of the text, and is recorded in Watts. | week -12, 0, 12, 24 | |
Secondary | Standard blood sample | As part of the usual assessment of the patients, standard blood samples (15ml) are drawn and analysed (4 visits x 15 ml = 60 ml per participant). The analyses include: Haemoglobin (Hgb), white blood cells, Bilirubin, ALAT, ASAT, INR, platelets, CRP, creatinine, urea, sodium, potassium, alkaline phosphatase albumin, coagulations factors II VII and X. | week -12, 0, 12, 24 | |
Secondary | Plasma concentrations of inflammatory markers | EDTA plasma will be collected at before and after 12 weeks of supervised training intervention, and before and after a single exercise session in week 6 to analyse specific for cytokines/myokines interactions e.g. TNF alfa and IL-6. | week -12, -6, 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04422223 -
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
|
||
Active, not recruiting |
NCT03863730 -
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
|
N/A | |
Completed |
NCT00913757 -
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
|
||
Completed |
NCT00525252 -
Efficacy of Baclofen in the Treatment of Alcohol Addiction
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06057870 -
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
|